null

null

null

null

null

null

null

null

null

null

null

null

null

0.06x Total Debt / Equity (Conservative)

Low direct sensitivity; pre-revenue biotech with ~$200M+ cash runway, minimal debt, funded by equity raises not leverage

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API drug substance sourcing from specialized European CROs/CMOs; 2) Rare raw material inputs for heme/erythroid pathway compounds concentrated in limited GMP suppliers

Essentially no international revenue currently; clinical-stage US-domiciled company, currency devaluation risk is negligible at this stage

Minimal forex exposure; operations and clinical trials primarily US-based with some EU trial sites, no material revenue in any currency other than USD

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single-source CMOs for tamibarotene and bitopertin API; substitution would require 12-24 months regulatory revalidation, representing non-substitutable critical path

Clinical-stage biopharmaceutical; cloud disruption would impair data management and trial operations but is not existential—paper/hybrid backup feasible within weeks

No secondary business model; pure-play drug development company with no SaaS, platform, or product revenue streams

Low API coupling risk; uses standard clinical data platforms (Medidata, Veeva); no proprietary API lock-in that would prevent migration within 60-90 days

Not applicable; revenue model is pharmaceutical drug royalties/sales, not an investment contract—Howey Test risk is negligible

Very High

Moderate GDPR exposure from EU clinical trial patient data; CCPA exposure limited; compliant under ICH E6 GCP framework but EU data transfer mechanisms require ongoing monitoring

Low antitrust risk; small-cap company targeting rare hematologic diseases with no dominant market position; orphan drug pricing scrutiny is primary regulatory concern

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue currently; 100% future revenue expected from milestone payments and eventual drug sales—transactional/event-driven biotech model

Future monetization via drug product sales and potential licensing/partnership milestones; no current commercial revenue

Orphan drug pricing model anticipated; comparable hematology drugs (e.g., luspatercept ~$100K+/year) suggest high list price, but payer negotiation and rebates compress net realized price by 30-50%

Moderate-to-high; rare disease designation and limited competition in MDS/polycythemia vera provide pricing leverage, but CMS drug negotiation and biosimilar risks constrain long-term power

Targeted 75-85% gross margin at commercial stage, consistent with small-molecule rare disease peers assuming third-party CMO manufacturing

No free-rider risk; prescription drug model with no open-source or public-good leakage; patient adherence is the primary retention variable

Sublinear growth model; commercial launch requires salesforce scaling but R&D productivity is not headcount-linear; doubling revenue would require ~30-40% headcount increase

Marginal cost of growth is primarily COGS (CMO manufacturing) and modest salesforce expansion; platform leverage improves after initial commercial infrastructure build

Not applicable; no franchise network exists

At 10x scale, CAC economics improve substantially via established KOL relationships and label expansion; hematologist universe is small (~3,000 US specialists) limiting addressable prescriber pool

No network effects present; drug efficacy and physician adoption are independent of user base size

-26.3% Return on Assets (Negative equity)

High recession resistance; rare hematologic diseases require treatment regardless of economic cycle; payer coverage (Medicare/Medicaid dominant) insulates from consumer spending cuts

Hematology/oncology specialists treating MDS, polycythemia vera, and related bone marrow failure diseases

Institutional payers (Medicare Part B/D, specialty pharmacy channels) and academic medical center treatment programs

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated entirely to future-state R&D pipeline (clinical trials, IND-enabling studies); no legacy infrastructure drag; ~85-90% of spend is R&D operating expense, not traditional capex

0001816736

IRON